Navigation Links
NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations
Date:3/31/2008

LAWRENCE, Mass., March 31 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Tom Shea has joined the Company as Senior Vice President of Manufacturing Operations, effective March 31, 2008. Mr. Shea will be responsible for all of NxStage's manufacturing operations, including the Company's five manufacturing facilities.

Mr. Shea joins NxStage with more than 20 years of operational management experience. Prior to joining NxStage, Mr. Shea held several leadership positions at Jabil Incorporated, a $12 billion Tier I contract manufacturer. Most recently, Mr. Shea served as Jabil's Global Business Unit Manager, supporting clients in the aerospace, defense and telecommunications industries. In this capacity, he developed operations, pricing and logistics strategies and implemented manufacturing plans that resulted in significant quarterly cost reductions. He previously served as Operations Manager at Jabil where he had full plant profit and loss responsibility for their Massachusetts facility.

"Tom comes from an industry built on aggressive cost management and I believe his experience working with regulated devices will be of tremendous benefit to NxStage," said Jeffrey H. Burbank, President & Chief Executive Officer of NxStage Medical. "Tom is a great fit for NxStage and we are extremely pleased to welcome him to the team."

Mr. Shea earned his M.B.A. at The University of Massachusetts and his B.S. in Production and Operations Management at Bryant University. He has completed the Operations Executive Leadership Program at Harvard University as well as Six Sigma Training.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at http://www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the contributions Mr. Shea will make to the Company's performance and operating results. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements. Certain factors which may affect future operating results are detailed in NxStage's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2007. In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.

Investor Relations Contact

Stephanie Marks for NxStage

1-888-698-6472

ir@nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NxStage Medical Announces Needle Supply Agreement with DaVita
2. NxStage Medical to Present at the Piper Jaffray Healthcare Conference on November 27, 2007
3. Arbios Announces SEPET(TM) Manufacturing Agreement With NxStage Medical
4. NxStage(R) Medical to Report Third Quarter 2007 Financial Results on Friday, November 2nd
5. NxStage Medical Provides Update on Medisystems Acquisition
6. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
7. ExonHit Appoints a New Management Board
8. Pharmasset Appoints Herbert J. Conrad as a Director
9. MacroChem Appoints David P. Luci as New CFO
10. Kosans Board of Directors Appoints Helen S. Kim as Chief Executive Officer
11. RainDance Appoints Becker Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
Breaking Biology Technology:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):